Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.

Authors :: Visentin A
Mauro FR
Scarfò L
Gentile M
Farina L
Reda G
Ferrarini I
Proietti G
Derenzini E
Cibien F
Vitale C
Sanna A
Pietrasanta D
Marchetti M
Murru R
Rigolin GM
Sportoletti P
Trimarco V
Cavarretta CA
Angotzi F
Cellini A
Ruocco V
Zatta I
Laurenti L
Molica S
Coscia M
Ghia P
Foà R
Cuneo A
Trentin L
Source :: American journal of hematology [Am J Hematol] 2023 Sep; Vol. 98 (9), pp. E237-E240. Date of Electronic Publication: 2023 Jun 29.
Publication Year :: 2023

Subjects :: Humans
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Sulfonamides therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Tumor Suppressor Protein p53 genetics
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Antineoplastic Agents therapeutic use

Full Text Access

Tools